Meet Laura Cheng. Laura is a nurse. She has acromegaly. She works as a clinical nurse and is currently enrolled in the endocrine program at Duke University. Laura’s connection to this disease gives her a unique perspective and will provide an invaluable resource to her patients. We caught up with Laura a few weeks ago. This is her story.
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk session 1 – April 7, 2022: Headaches and pituitary tumors
In the first Pituitary World News LIVE TALK radio-style program, our guest Dr. Manish Aghi discusses the many facets of headaches and pituitary tumors.
In today’s podcast directed to physicians, PWN co-founder Dr. Lewis Blevins discusses the drug Recolev® (levoketoconazole) recently approved by the FDA to treat endogenous Cushing’s Syndrome.
A Cushing’s tale: Two images. Eight months. Same person.
To launch the eighth season of the Pituitary World News podcast, we welcome to our microphones, Brandy. Brandy has quite a story to tell us about her battle with Cushing’s disease.
In this podcast directed to physicians, Dr. Lewis Blevins shares his vast experience of 30 years treating patients with central hypothyroidism.
In the last podcast in the series on the drugs available to manage hypercortisolism, Dr. Blevins discusses mifepristone, trade name Korlym®.
Pasireotide (Signifor, Signifor LAR)
This is the fourth podcast in a series of five on medications to treat Cushing’s disease. Today Dr. Blevins discusses Pasireotide, trade names Signifor and Signifor LAR.
Our third podcast in the series is on osilodrostat (trade name Isturisa®), a drug approved by the FDA in the US and the European Medicines Agency (EMA) to treat hypercortisolism in patients who are not candidates for surgery or those that surgery did not work. In this podcast, Dr. BLevins takes us inside his clinical practice to share his experiences with the drug.
The second podcast in our series on the medical management of hypercortisolism focuses on the drug metyrapone. Dr. Blevins discusses the drug uses, how it works, and its side effects.
Coming up next, a discussion on the drug Isturiza® (osilodrostat).
This is the first in our series of five podcasts on the medical management of Hypercortisolism due to Cushing’s disease. Today Dr. Blevins discusses the drug Ketoconazole. Tune in tomorrow to listen to the second podcast in the series on the use of Metyrapone, and on Monday, don’t miss the podcast on Isturisa® (osilodrostat).
The challenges and opportunities in new hypercortisolism drugs
Today we welcome three renowned experts in the development of drugs to treat hypercortisolism. Dr. Blevins and I discuss their research, clinical trials, challenges, and opportunities for these essential medications that could immensely affect patient well-being and quality of life. This discussion touches on the fascinating details of hypercortisolism and the developments now and in the future.
Acromegaly: the last 30 years
In this Podcast, Dr. Blevins gives us a perspective of the last 30 years on the developments in this field. Like many other conditions, the advances in therapy, imaging, surgery techniques, diagnostic testing, and clinical knowledge have been nothing short of remarkable.
Podcast – Ride for acromegaly: 1,200 miles down; 680 miles to go.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.